Skip to main content
. 2017 Dec 22;107(5):380–388. doi: 10.1007/s00392-017-1193-z

Table 1.

Baseline characteristics of ASCVD patients using moderate-/high-intensity statins, by annual cohort

Characteristics 2012 (n = 14,058) 2013 (n = 15,383) 2014 (n = 16,316)
n % n % n %
Age, mean (SD) 70.6 (10.4) 70.6 (10.5) 70.8 (10.6)
Female 4977 35.4 5,276 34.3 5629 34.5
Private health insurance coverage 1195 8.5 1,323 8.6 1371 8.4
High-intensity statin use 1130 8.0 1629 10.6 1956 12.0
Ezetimibe use 1136 9.5 1209 7.9 1107 6.8
Type 2 diabetes 4414 31.4 4646 30.2 5042 30.9
Hypertension 10,558 75.1 11,399 74.1 12,123 74.3
Coronary heart disease 9827 69.9 10,676 69.4 11,274 69.1
Myocardial infarction 3233 23.0 3615 23.5 3671 22.5
Ischemic stroke 731 5.2 831 5.4 946 5.8
Peripheral artery disease 2095 14.9 2184 14.2 2496 15.3
Chronic kidney disease 548 3.9 646 4.2 767 4.7
COPD 1237 8.8 1431 9.3 1566 9.6
Heart failure 1870 13.3 2046 13.3 2350 14.4
Depression 1434 10.2 1615 10.5 1811 11.1
Charlson Comorbidity Index mean (SD) 1.8 (1.4) 1.8 (1.4) 1.9 (1.5)

COPD chronic obstructive pulmonary disease, SD standard deviation